Rachel G Miller

Contributions to Public Health

• Epidemiology and pathogenesis of complication development in type 1 diabetes: I have been a collaborator on the Pittsburgh Epidemiology of Diabetes Complications (EDC) study since 2005. I am particularly interested in the heterogeneity of diabetes complication risk and how longitudinal data can be leveraged to optimize identification of risk factors to prevent and delay complications.
  • Miller RG, Orchard TJ, Costacou T. 30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-Term Patterns of Glycemic Control. Diabetes Care. 2022; 45(1): 142-150.
  • Miller RG, Anderson SJ, Costacou T, Sekikawa A, Orchard TJ. Hemoglobin A1c and cardiovascular disease incidence in type 1 diabetes: An application of joint modeling of longitudinal and time-to-event data in the Pittsburgh Epidemiology of Diabetes Complications Study. American Journal of Epidemiology. 2018; 187(7): 1520-1529.
• Interplay between genetic/epigenetic factors and glycemic control with respect to risk of diabetes complications: I am PI of an R01 which aims to identify genetic variants and inflammatory proteins associated with susceptibility to myocardial infection or fatal CAD in type 1 diabetes and how those associations are affected by glycemic control (R01HL161879). I am also the past PI of a project examining DNA methylation and multiple complications of type 1 diabetes, funded by the American Diabetes Association.
  • Zhou J, Mychaleckyj JC, Onengut-Gumuscu S, Orchard TJ, Costacou T, Miller RG. DNA methylation and 28 year incidence of two neuropathy phenotypes in type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications cohort study. Diabetologia. 2025; Online before print.
  • Miller RG, Mychaleckyj JC, Onengut-Gumuscu S, Feingold E, Orchard TJ, Costacou T. DNA methylation and 28-year cardiovascular disease risk in type 1 diabetes: The Epidemiology of Diabetes Complications (EDC) cohort study. Clinical Epigenetics. 2023; 15: 122.
• Women’s health research: I am the PI of an American Diabetes Association Innovative Clinical and Translational Science Women’s Health Award to study complication risk factors across different life stages in women living with type 1 diabetes (Grant #7-23-ICTSWH-19). The study aims to advance understanding of sex-specific complication risk and inform optimal timing for interventions to reduce complication risk. I am also a coordinating center statistician for the Study of Women’s Health Across the Nation (SWAN).
  • Miller RG, Orchard TJ, Costacou T. Sex-Specific Blood Pressure Trajectories and Cardiovascular Disease in Type 1 Diabetes: 32-Year Follow-up of the Pittsburgh Epidemiology of Diabetes Complications Cohort. Diabetes Care. 2025; 48(4):
• Statistical analyses of efficacy and translational effectiveness trials: I have served as a statistician on several efficacy trials and community-based translational/effectiveness trials of lifestyle modifications to prevent type 2 diabetes and cardiovascular disease. These include Physical Activity and Sedentary Behavior Change Impact on Lifestyle Intervention Effects for Diabetes Translation; Diabetes Prevention Translation Project - The healthy LIFESTYLE Program; and Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST).
  • Quaytman JA, David NL, Venugopal S, Amorim T, Beatrice B, Toledo FGS, Miller RG, Steinhauser ML, Fazeli PK. Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial. Contemporary Clinical Trials. 2024; 146: 107698.
  • Kriska AM, Devaraj SM, Kramer K, Napoleone JM, Rockette-Wagner B, Eaglehouse Y, Arena VC, Miller RG. The likely underestimated impact of lifestyle intervention: Diabetes Prevention Program translation examples. Am J Prev Med. 2022; 62(4): e248-e254.